Prodapt Acquires Silicon Valley-Based Synophic Worldwide
Prodapt, the leading consulting, technology & managed transformational services provider to the Connectedness vertical, announced that it acquired Synophic Worldwide, a global company providing network transformational and managed services to Digital Service Providers (DSPs), ISVs, product and platform companies.
Founded in 2009, Synophic employs over 600+ people globally, and is a trusted partner for leading OEMs/NEMs, ISVs, and Enterprises for their technical depth and matured managed services execution in the network design, engineering, and NOC services. This acquisition further expands Prodapt’s presence in the US/LATAM regions and provides an entry into the APAC markets including Japan, Philippines, and Australia.
Prodapt had earlier announced plans to invest US$45M in deepening its capabilities in network virtualization and cloudification segment, and the Synophic acquisition is part of this investment strategy. Additional investments have been planned in areas around Network cloud, Autonomous networks, and NetSecOps.
With Synophic’s acquisition, Prodapt strengthens its network services portfolio and enables Prodapt to offer end-to-end services around network transformation, network orchestration, and automation to network-managed services.
“I am delighted to welcome Kondal Rao and the Synophic Worldwide team to the Prodapt family,” said Vedant Jhaver, Chairman and CEO of Prodapt. “Synophic’s wide range of capabilities in network solutions, cloud, IoT, mobility, data centers, and security augments our portfolio of network transformational services and further expands our services that help accelerate connectedness.”
Synophic is Prodapt’s third acquisition this financial year. Prodapt earlier announced the acquisitions of Innovative Logic and SLR Dynamics. These acquisitions further enhance Prodapt as the partner of choice for the largest companies in the Connectedness vertical.
“Joining forces with Prodapt will help expand our managed services and network transformation portfolio. This will also open a plethora of growth potential for the employees of Synophic,” said Kondal Rao, CEO, Synophic Worldwide. “I am pleased to be part of the Prodapt team and excited about the multi-fold scale with which we can operate and leverage Prodapt’s transformational expertise in delivering solutions to our customers.”
Avendus Capital was the exclusive financial advisor to Prodapt on this transaction while BDA Partners acted as the exclusive financial advisor to Synophic Worldwide.
About Prodapt: www.prodapt.com
Prodapt has a singular focus on the Connectedness vertical. Prodapt’s customers range from telecom operators, digital / multi-service providers (D/MSPs), technology and digital platform companies in the business of connectedness.
Prodapt builds, integrates, and operates solutions enabling next-generation technologies and innovations. Prodapt works with global leaders including AT&T, Verizon, CenturyLink, Adtran, Vodafone, Liberty Global, Windstream, Virgin Media, Rogers, Deutsche Telekom among many others. Prodapt’s customers today help more than a billion people and five billion devices stay connected.
Prodapt has offices in North America, Europe, Latam, India, and Africa. It is part of the 120-year-old business conglomerate, The Jhaver Group, which employs over 22,000 people across 64+ locations globally.
About Synophic Worldwide:https://www.synophic.com/
Synophic Worldwide is a global provider of Managed Services and Network Transformation services for enterprises and service providers. Synophic provides design, automation, integration services and manages large, complex, and mission-critical environments for customers in 20+ countries with operations in the US, Australia, Japan, Mexico, Philippines, Colombia, India, and Chile. Synophic specializes in Service Provider Mobility, Wireless, IoT, Advanced and Adaptive Networking, Service Provider and Enterprise Networks, Data Centers, Cloud, and Security. Synophic offers solutions from Edge to Core to Cloud and partners with innovative technology leaders, OEMs / NEMs, ISVs, and some of the world’s best-known customers and partner brands.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220118005675/en/
Contact information
Media Contact : Krishna Kumar N
Associate Director-Marketing, Prodapt
krishnakumar.n@prodapt.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new